AU2002221542A1 - Use of heart-specific transcription factors of the basic helix-loop-helix type for treating cardiac power failure - Google Patents

Use of heart-specific transcription factors of the basic helix-loop-helix type for treating cardiac power failure

Info

Publication number
AU2002221542A1
AU2002221542A1 AU2002221542A AU2154202A AU2002221542A1 AU 2002221542 A1 AU2002221542 A1 AU 2002221542A1 AU 2002221542 A AU2002221542 A AU 2002221542A AU 2154202 A AU2154202 A AU 2154202A AU 2002221542 A1 AU2002221542 A1 AU 2002221542A1
Authority
AU
Australia
Prior art keywords
helix
heart
loop
power failure
transcription factors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002221542A
Inventor
Ingo Morano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Original Assignee
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft filed Critical Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Publication of AU2002221542A1 publication Critical patent/AU2002221542A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2002221542A 2000-11-07 2001-11-07 Use of heart-specific transcription factors of the basic helix-loop-helix type for treating cardiac power failure Abandoned AU2002221542A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10055157 2000-11-07
DE10055157 2000-11-07
PCT/DE2001/004132 WO2002038781A1 (en) 2000-11-07 2001-11-07 Use of heart-specific transcription factors of the basic helix-loop-helix type for treating cardiac power failure

Publications (1)

Publication Number Publication Date
AU2002221542A1 true AU2002221542A1 (en) 2002-05-21

Family

ID=7662441

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002221542A Abandoned AU2002221542A1 (en) 2000-11-07 2001-11-07 Use of heart-specific transcription factors of the basic helix-loop-helix type for treating cardiac power failure

Country Status (3)

Country Link
AU (1) AU2002221542A1 (en)
DE (1) DE10154224A1 (en)
WO (1) WO2002038781A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999028469A1 (en) * 1997-12-04 1999-06-10 Genzyme Corporation Compositions and methods for inducing gene expression
AU2807701A (en) * 1999-08-13 2001-03-13 Mei LEE Cardiomyocyte regeneration

Also Published As

Publication number Publication date
DE10154224A1 (en) 2002-06-20
WO2002038781A1 (en) 2002-05-16

Similar Documents

Publication Publication Date Title
AU6461000A (en) Continuity of voice carried over dsl during power failure
EP1452191A3 (en) Porous tissue scaffoldings for the repair or regeneration of tissue
AU2002218742A1 (en) Application of photochemotherapy for the treatment of cardiac arrhythmias
AU2001275938A1 (en) Cardiac photoablation instruments
AU4198500A (en) Suture-passing forceps
AU2001249881A1 (en) Method of treating the heart
AU6104200A (en) Surgical blade coatings
AU2001271530A1 (en) Method of hard tissue repair
AU6533400A (en) Power door kit
AU2001259702A1 (en) Tissue regrafting
AU2002367023A1 (en) Compositions and methods for treating heart failure
AUPR074500A0 (en) Treatment of t cell disorders
AU2001226910A1 (en) Electrolytic treatment
AU2002365057A1 (en) Compositions and methods for treating heart failure
AU2001260834A1 (en) The treatment of herpes
AU3235100A (en) Prothease inhibitors
AU2021601A (en) Composition for the treatment of dandruff
AU1878201A (en) Composition for the treatment of damaged tissue
AU2002249947A1 (en) Inhibition of protein-phosphatases for the treatment of heart failure
AU2462700A (en) Steel-stiffened wooden girder
AU5394300A (en) Tissue engineering
AU6483600A (en) Collision-resistant structure
AU2002221542A1 (en) Use of heart-specific transcription factors of the basic helix-loop-helix type for treating cardiac power failure
AU1522101A (en) Heparanase inhibitors for the treatment of heart failure
AU2003299507A1 (en) Hop - a novel cardiac-restricted transcriptional factor potentially useful for cardiac regeneration and specification